These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30027395)

  • 21. JAK2V617F allele burden is associated with transformation to myelofibrosis.
    Koren-Michowitz M; Landman J; Cohen Y; Rahimi-Levene N; Salomon O; Michael M; Amariglio N; Nagler A
    Leuk Lymphoma; 2012 Nov; 53(11):2210-3. PubMed ID: 22524513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of polycythaemia vera: a critical review of current data.
    McMullin MF; Wilkins BS; Harrison CN
    Br J Haematol; 2016 Feb; 172(3):337-49. PubMed ID: 26492433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How I treat polycythemia vera.
    Passamonti F
    Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moving toward disease modification in polycythemia vera.
    Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
    Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial chronic myeloproliferative disorders: the state of the art.
    Rumi E
    Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
    Passamonti F; Elena C; Schnittger S; Skoda RC; Green AR; Girodon F; Kiladjian JJ; McMullin MF; Ruggeri M; Besses C; Vannucchi AM; Lippert E; Gisslinger H; Rumi E; Lehmann T; Ortmann CA; Pietra D; Pascutto C; Haferlach T; Cazzola M
    Blood; 2011 Mar; 117(10):2813-6. PubMed ID: 21224469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
    Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
    Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib in a Child With JAK2 Exon 12 Mutant Polycythemia Vera.
    Stoops K; Kuril S
    J Pediatr Hematol Oncol; 2023 May; 45(4):e502-e505. PubMed ID: 36161965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
    Maffioli M; Mora B; Passamonti F
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary and future strategies in polycythemia vera.
    Waksal JA; Tremblay DA
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101370. PubMed ID: 36333064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
    Sørensen AL; Mikkelsen SU; Knudsen TA; Bjørn ME; Andersen CL; Bjerrum OW; Brochmann N; Patel DA; Gjerdrum LMR; El Fassi D; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Ellervik C; Pallisgaard N; Thomassen M; Kjær L; Skov V; Hasselbalch HC
    Haematologica; 2020 Sep; 105(9):2262-2272. PubMed ID: 33054051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.